Anicom Holdings, Inc.
8715・Prime Market・Insurance
Business
Anicom Holdings, Inc. is an insurance holding company founded in 2000 that specializes in pet insurance. Its core subsidiary, Anicom Insurance, Inc., has maintained the No.1 share in the domestic pet insurance market for 17 consecutive years since 2009, boasting 1,392,772 policies in force (as of the end of March 2026). Its business domains extend widely beyond the core Non-life Insurance Business to include operation of breeder matching sites (Pet-related Internet Services Business), operation of animal hospitals (over 58 hospitals), the Health Innovation Business for oral and gut care products, and peripheral businesses such as genetic testing and medical record management systems. The company aims to be an infrastructure player that consistently supports pets "from upstream to downstream," from before birth through advanced medical care.
Business Model
The main revenue source is net premiums written (¥64,103 million in FY2026 (ending March 2026)). New contracts are acquired through the NB channel of 1,352 pet shop agencies with 5,122 stores, as well as general channels, building up annual renewable premium income. The Counter Settlement System, the industry's first of its kind and with the largest number of participating hospitals (approximately 7,000), enhances customer convenience and operational efficiency simultaneously, processing approximately 90% of the roughly 4.8 million annual claims through the system to reduce costs. The company has a structure in which data and networks accumulated in the insurance business are leveraged in adjacent businesses, creating synergies across the group as a whole.
Company Strengths
Anicom Insurance has maintained the No.1 share of the domestic pet insurance market for 17 consecutive years, from 2009 to 2025. As of the end of March 2026, the number of policies in force stood at 1,392,772, a solid increase of 104,849 (8.1%) from the end of the previous fiscal year. New policy acquisitions also continued to accumulate steadily, reaching 266,231 (up 8.3% year on year), forming a customer base that competitors would find difficult to replicate in a short period of time.
The company built Japan's first Counter Settlement System, which as of March 2026 had contracts with approximately 7,000 animal hospitals nationwide (more than 50% of all animal hospitals in Japan). Approximately 90% of the roughly 4.8 million annual insurance claims are processed through this system, significantly reducing administrative costs. The number of hospitals using this system far exceeds that of other companies, forming a barrier to entry in terms of both customer convenience and operational efficiency.
The group employs 121 licensed veterinarians, making it one of the companies in Japan with the largest concentration of veterinarians. It also employs a wide variety of specialists, including holders of doctorates in agricultural science, natural science, pharmacy, and dentistry, as well as lawyers, certified public accountants, actuaries, patent attorneys, and data scientists. This diverse talent pool is a source of improved quality in insurance underwriting and assessment as well as R&D capabilities that are difficult for other companies to replicate in a short period of time.
ENVALITH's Perspective
Performance Trend
Revenue grew for five consecutive periods, rising from ¥53,022 million in FY2022 to ¥73,846 million in FY2026 (a CAGR of approximately 8.6%). Meanwhile, net income had been on an upward trend, increasing from ¥2,112 million in FY2022 to ¥3,246 million in FY2025, but in FY2026 it fell sharply to ¥2,204 million, down approximately 32.1% year on year. ROE also declined to a revised 7.7%. A rise in the loss ratio and upfront investment costs in peripheral businesses are believed to have weighed on profitability. Note that, per the correction dated May 13, 2026, return on equity was revised from 8.0% to 7.7%.
Growth Strategy
Twin-track strategy of strengthening the profitability of the pet insurance business and expanding businesses that create synergies from upstream to downstream
Acquiring new contracts through strengthened sales activities in the NB channel (4,986 pet shop agencies) and the general channel, as well as by promoting products bundled with Dobutsu Kenkatsu. At the same time, aiming to control the loss ratio and improve profitability by enhancing underwriting review and assessment accuracy through a team of 103 veterinarians.
Promoting the expansion of animal hospital operations (58 hospitals) by Anicom Advanced Medical Research Institute, advancing hospital succession, and expanding the adoption of regenerative medicine (809 participating hospitals, 492 stem cell administration cases). The upfront investment phase is continuing, and scaling up toward monetization remains a challenge.
Sales from the breeding business of Florence Co., Ltd., which became a subsidiary in March 2024, contributed to a sharp expansion in ordinary revenue from Other Businesses, up 160.2% year-on-year to ¥1,907 million. The aim is to create group synergies by incorporating upstream domains.
Promoting the development and expansion of genetic testing technology that can measure personality, breed, coat color, and constitution all at once, and developing sales channels for oral & gut care products such as CRYSTAL JOY and 7Days Food, primarily through directly operated animal hospitals. Revenue contribution remains at a limited stage.
Last updated: July 19, 2026